RecruitingPhase 1NCT07521345

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and the Food Effect of HSK55879 Tablets in Healthy Subjects.

Sponsor

Haisco Pharmaceutical Group Co., Ltd.

Enrollment

46 participants

Start Date

Mar 20, 2026

Study Type

INTERVENTIONAL

Conditions

Healhty

Summary

This is a single-center, random, double blind, placebo control clinical study to evaluate the safety, tolerability pharmacokinetics and food effect of HSK55879 in healthy subjects

Eligibility

Min Age: 18 YearsMax Age: 45 Years

Inclusion Criteria4

Able to understand the nature, purpose, and requirements of the study, as well as the potential risks and adverse reactions, and have signed the written informed consent form prior to the start of the study;
Healthy subjects aged 18 to 45 years (inclusive) at screening, male or female;
Body weight ≥50 kg for male subjects and ≥45 kg for female subjects at screening, with a body mass index (BMI) within the range of 19.0-28.0 kg/m² (inclusive);
Subjects (including their partners) agree to have no pregnancy plan from 14 days before screening until 3 months after the last dose, and agree to use reliable contraceptive measures during this period.

Exclusion Criteria13

Any history of disease that, in the investigator's judgment, may affect the safety evaluation of the subject or the in vivo disposition of the study drug,
Physical examination, vital signs, laboratory tests，abdominal ultrasound, or chest X-ray findings that are judged by the study physician to be clinically significant abnormalities;
Previous or current gastrointestinal, hepatic, renal, or other diseases known to interfere with drug absorption, distribution, metabolism, or excretion;
abnormal HbA1c at screening;
Abnormal liver function test results
Estimated glomerular filtration rate (eGFR) calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation <90 mL/min/1.73 m² at screening;
Routine 12-lead electrocardiogram (ECG) findings that are not consistent with normal cardiac conduction and function.
History of gastrointestinal diseases, with current symptoms of digestive discomfort ;
Current or past history of drug abuse, or a positive urine drug screen at screening;
Positive test for hepatitis B surface antigen (HBsAg), hepatitis C antibody, syphilis antibody, or human immunodeficiency virus (HIV) antibody at screening;
Pregnant or breastfeeding females;
Subjects who, in the investigator's opinion, have poor compliance or any other factor that makes them unsuitable for participation in this study.
\-